UNSPSC 51144002: Alfetamine

This classification denotes a cns stimulant with the molecular formula C11H15N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) Q3V87119BP, chemically known as 1-phenylpent-4-en-2-amine but more generally known as Alfetamine, which bears US NIH Compound Identifier 20254. European Medicines Agency schedules Amfetamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05318MIG.

ALFETAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule alfetamine under HS 29214980 and SITC 51454. SMILES: C=CCC(CC1=CC=CC=C1)N.

UNSPSC 51144002 Alfetamine, a Commodity code, does not reflect the actual scope of work being solicited under it in recent state and local procurement. The three recent opportunities tagged to this code pursue naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription program design—none of which are alfetamine or related sympathomimetic agents. The mismatch suggests either a classification error in the procurement records or a divergence between the code's nominal scope and actual purchasing activity.

The geographic spread across recent opportunities spans Florida (Seminole County), Texas (Health and Human Services Commission), and Minnesota (MMCAP, serving multiple states including Oregon), with issuing bodies ranging from county health departments to state health commissions and multistate cooperative purchasing alliances. Representative recent opportunities include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a due date of July 26, 2023; the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs posted April 3, 2026; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026. Without clarification of whether this code is correctly assigned to pharmaceutical and medical-supply procurement or is simply mislabeled in the available solicitation records, the code shows little activity aligned to alfetamine itself.